Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kymera Therapeutics, Inc.

NASDAQ: KYMR · Life Sciences · 3 alerts · CIK 1815442

Share price
$125.85Close, Nov 16
Market cap
$10.7B
Shares outstanding
85.37MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kymera Therapeutics, Inc. filings on SEC EDGAR ↗

7:16 AM ET 10-Q
Financial Results

Kymera Therapeutics Q3 2026 Results: Net Loss of $132M, Loss Widens

Kymera Therapeutics reported collaboration revenue of $99.4 million for the nine months ended September 30, 2026, a significant increase from $36.3 million in the prior year. Despite this, the company recorded a net loss of $262.4$ million for the period due to rising research and development expenses, which reached $346.2 million.

Key figure
Net loss $132M
7:11 AM ET 8-K
Financial Results

Kymera Therapeutics Financial Results

Kymera Therapeutics reported financial results for the third quarter ended September 30, 2026, and announced positive Phase 1 data for its IRF5 degrader, KT-579. The company remains well-capitalized with $1.6 billion in cash, providing a runway into 2029, and expects topline Phase 2b data for its STAT6 degrader, KT-621, by year-end 2026.

Term
Q3 2026

“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology. With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape.”

Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics

“The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism.”

Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.